Redwood City, Calif.July 20, 2015 – C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced the publication of excellent safety and dosing data related to the company’s Coldplay Cryoballoon™ Focal Ablation System.  Results from the prospective, non-randomized study titled, “Treatment of Barrett’s Esophagus with a novel focal cryoablation device: a safety and feasibility study” were published in the latest edition of the scientific journal Endoscopy.

Click here to see full release.